Nav: Home

Nebraska leads $11 million study to develop radiation exposure drugs

January 14, 2019

The U.S. Department of Defense has turned to the University of Nebraska to jumpstart the development of drug therapies to protect military service members from the effects of radiation exposure.

In an environment where for-profit pharmaceutical companies are often reluctant to embark upon financially risky drug discovery efforts, the unique four-pronged partnership established by the university and the Department of Defense could shorten the U.S. military's wait for drugs that prevent and counteract the effects of radiation exposure.

"It's an exciting collaboration among the federal government, our state university and two of its premier research campuses -- University of Nebraska Medical Center and the University of Nebraska-Lincoln -- and consultants from private pharma who are Nebraska alumni," said David Berkowitz, professor of chemistry.

This team operates under the auspices of the university's National Strategic Research Institute, one of 13 university-affiliated research centers. Nebraska has the lone research center entrusted by the military to work on chemical, biological, radiological and nuclear threats.

"This research represents the broad capacity of the University of Nebraska and its alumni consultants to tackle potentially hazardous radiation exposures around the world," said Lt. Gen. (Ret.) Robert Hinson, founding executive director of the National Strategic Research Initiative.

The University of Nebraska project for the Defense Health Agency, and in collaboration with Armed Forces Radiobiology Research Institute, has reached a second increment -- potentially awarding nearly $11 million in federal funding over the next five years. Nebraska researchers will look for therapeutics candidates the U.S. military would need to protect troops from radiation in case of exposure, as in a nuclear accident or a nuclear weapons incident.

Leveraging the full, collaborative strength of a united university system -- multiple campuses, a network of successful alums -- directed by the Department of Defense, is something new for the university.

"I've never been involved with anything like that before," Berkowitz said. "This team came together as a joint vision between the team leadership and our (Department of Defense) funders and it's pretty unusual across the country to see such a public-private-government partnership."

In fact, the university hopes this opens the door to continued partnership with private pharma in the longer term, through identifying and developing therapeutic candidates that have dual-purposing potential, Berkowitz said. Berkowitz is co-primary investigator of the project, with Ken Bayles, professor of pathology and microbiology at UNMC.

Bayles said if private pharmaceutical companies are leaving a gap, the University of Nebraska is eager to step in.

"We've pitched this concept to develop a virtual pharmaceutical company, a drug development pipeline that would coordinate the activities of all the expertise we have across all of our campuses and develop capabilities to move molecules forward for drug development," he said.

Handfuls of NU's top scientists will work on medicinal chemistry, metabolomics and bioinformatics in order to move potential drug candidates toward clinical trials. "We'll be coordinating all of these aspects like a pharmaceutical company does," Bayles said. "If we do it right, this pipeline concept is an opportunity to build the economy in Nebraska, build the pharmaceutical industry in Nebraska."

Berkowitz said the new multi-pronged, multi-campus team is complex, but, "it's working pretty well."

"We are extremely proud to be affiliated with this research and the impact it can have for the Department of Defense, Defense Health Agency and other agencies as well," Lt. Gen. Hinson said.

Consultants from pharmaceutical industry will advise Nebraska scientists on the drug development effort.

Collaborators include the following University of Nebraska scientists, who bring key expertise to the project to establish a drug development pipeline that could speed the process of developing new drugs at the Armed Forces Radiobiology Research Institute to counteract the effects of radiation exposure:

* Samuel Cohen, UNMC, toxicology. * Patrick Dussault, UNL, synthetic chemistry. * Babu Guda, UNMC, bioinformatics. * Tomas Helikar, UNL, computational systems biology. * DJ Murry, UNMC, pharmacokinetics and pharmacogentics. * Rebecca Oberley-Deegan, UNMC, radiation therapeutics. * Robert Powers, UNL, metabolomics.

Additionally, multiple University of Nebraska alums, all doctoral scientists, with current or former experience in private pharma, also are involved. This experienced consultant team includes Eugene Cordes of Philadelphia (honorary degree, UNL, 2009), Norton Peet, Holland, Mich. (Ph.D., UNL, chemistry, 1970), Kevin Woller, Antioch, Ill. (Ph.D., UNL, chemistry , 1996), Chad Briscoe, Overland Park, Kan. (Ph.D., UNL, chemistry, 2009), Ryan Hartung, Tuscon, Ariz. (B.S., UNL, chemistry, 2000).

"They are appreciative of the opportunity to give back to their home institution," said Berkowitz. "They really like the idea of the Lincoln and Omaha campuses collaborating. They really like working for the DoD. There is a patriotic aspect of helping the country and protecting our troops using the tools of biomedical science.

"That's something that has made this project special for all of us."
-end-


University of Nebraska-Lincoln

Related Radiation Articles:

Fragmenting ions and radiation sensitizers
The anti-cancer drug 5-fluorouracil (5FU) acts as a radiosensitizer: it is rapidly taken up into the DNA of cancer cells, making the cells more sensitive to radiotherapy.
'Seeing the light' behind radiation therapy
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime.
Radiation contamination at a crematorium
Radioactive compounds known as radiopharmaceuticals are used in nuclear medicine procedures to diagnose and treat disease.
First study of terahertz radiation in liquids
A research team from ITMO University and the University of Rochester (the USA) conducted a study on the formation of terahertz radiation in liquids.
A new way to create Saturn's radiation belts
A team of international scientists from BAS, University of Iowa and GFZ German Research Centre for Geosciences has discovered a new method to explain how radiation belts are formed around the planet Saturn.
A better device for measuring electromagnetic radiation
Researchers have developed a better bolometer, a device for measuring electromagnetic radiation.
New material detects the amount of UV radiation and helps monitor radiation dose
Researchers at the University of Turku, Finland, have developed a synthetic SensoGlow™ material that detects the quantity and quality of ultraviolet radiation from the Sun or other sources.
A new radiation detector made from graphene
Graphene is a remarkable material: light, strong, transparent and electrically conductive.
New measurements to guide radiation therapy
When ionizing radiation passes through living tissue, it interacts with molecules present in the cells, stripping away electrons and producing charged species known as ions.
Liquids take a shine to terahertz radiation
In a significant breakthrough, scientists at the Tata Institute of Fundamental Research (TIFR), Mumbai have devised a high power radiation source in the much sought after terahertz (THz) region of the electromagnetic spectrum.
More Radiation News and Radiation Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.